A5070503430- Immune Cell Function and Interaction
- Inflammatory Biomarkers in Disease Prognosis
- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Cellular Mechanics and Interactions
- Immune cells in cancer
- Cytokine Signaling Pathways and Interactions
- Microtubule and mitosis dynamics
- NF-κB Signaling Pathways
- Cancer Cells and Metastasis
- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- COVID-19 Clinical Research Studies
- Cell death mechanisms and regulation
- Retinoids in leukemia and cellular processes
- vaccines and immunoinformatics approaches
German Cancer Research Center
2018-2023
Deutschen Konsortium für Translationale Krebsforschung
2021-2023
University of Tübingen
2021-2023
Max Planck Institute for Medical Research
2019
Reutlingen University
2019
Cancer cell invasion through physical barriers in the extracellular matrix (ECM) requires a complex synergy of traction force against ECM, mechanosensitive feedback, and subsequent cytoskeletal rearrangement. PDMS microchannels were used to investigate transition from mesenchymal amoeboid cancer cells. Migration was faster narrow 3 μm-wide channels than wider 10 μm channels, even absence cell-binding ECM proteins. Cells permeating exhibited blebbing had smooth leading edge profiles,...
T-cell immunity is central for control of COVID-19, particularly in patients incapable mounting antibody responses. CoVac-1 a peptide-based activator composed SARS-CoV-2 epitopes with documented favorable safety profile and efficacy terms SARS-CoV-2-specific response. We here report Phase I/II open-label trial (NCT04954469) 54 congenital or acquired B-cell deficiency receiving one subcutaneous dose. Immunogenicity CoVac-1-induced responses are the primary secondary endpoints, respectively....
NK cells play an important role in tumor immunosurveillance. Their reactivity is governed by various activating and inhibitory surface receptors, which include several members of the TNF/TNF receptor family. For more than 50 years, it has been recognized that immunosurveillance particular cell antitumor largely influenced platelets, but underlying mechanisms remain to be fully elucidated. Here we report upon activation, reportedly occurs following interaction with cancer cells, platelets...
Owing to their key role in several diseases including cancer, activating and inhibitory immune checkpoint molecules are increasingly exploited as targets for immunotherapy. Recently, we demonstrated that platelets, which largely influence tumor progression evasion, functionally express the ligand of molecule GITR. This immunoreceptor modulates effector functions T cells NK with its function varying dependent on cellular context activation state. Here, provide a comparative analysis...
Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes STS are still limited. As result, especially in metastatic disease, prognosis is dismal. The ligands the activating immunoreceptor NKG2D (NKG2DL) commonly expressed STS, but generally absent healthy tissues. This provides rationale utilization NKG2DL as targets immunotherapeutic approaches. We here report on preclinical characterization bispecific fusion proteins...
In conventional T cells, OX40 has been identified as a major costimulating receptor augmenting survival and clonal expansion of effector memory cell populations. regulatory (Treg) signaling suppresses cellular activity differentiation. However, clinical trials investigating agonists to enhance anti-tumor immunity, showed only limited success so far. Here we show that platelets from breast cancer patients express relevant levels OX40L platelet (pOX40L) inversely correlates with...
Although treatment options of acute myeloid leukemia (AML) have improved over the recent years, prognosis remains poor. Better understanding molecular mechanisms influencing and predicting efficacy may improve disease control outcome. Here we studied expression, prognostic relevance functional role tumor necrosis factor receptor (TNFR) family member Receptor Activator Nuclear Factor (NF)-κB (RANK) in AML. We conducted an experimental ex vivo study using leukemic cells 54 AML patients....
Abstract T-cell immunity is central for the control of COVID-19, in particular patients incapable to mount a humoral immune response. We previously reported on favorable safety profile and efficacy terms induction SARS-CoV-2-specific responses by CoVac-1, peptide-based activator, composed SARS-CoV-2 epitopes derived from various viral proteins, combined with toll-like receptor 1/2 agonist XS15 1 . conducted Phase I/II open-label trial recruiting 54 congenital or acquired B-cell deficiency...
<h3>Background</h3> The activating immunoreceptor NKG2D is expressed on cytotoxic lymphocytes (CTL) like NK cells, CD8<sup>+</sup> T cells and γδ cells. It potently stimulates CTL effector functions upon recognition of its ligands (NKG2DL) that are generally absent healthy tissue, but induced by cellular stress including malignant transformation. Recent studies demonstrated – somewhat surprisingly - also the receptor can be tumor various origins may affect growth metastasis. Here we report...
Abstract Acute myeloid leukemia (AML) is the most common form of acute in adults. Untreated, AML leads to death within months after first symptoms. Combinatorial chemotherapy, mostly using a pyrimidine analog together with an anthracycline, made this previously incurable disease medicable, and response remission-inducing chemotherapy strongly correlates patient outcome. Despite advances treatment over recent years, still has poor prognosis average 5-year survival rate 30%. A better...